728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads
728 x 90 Leaderboard Ads

Genprex Recognized As Finalist In Technology Innovation Category For Fierce Innovation Awards

THIS POST WAS ORIGINALLY PUBLISHED ON THIS SITE Click Here To Read Entire Article

AUSTIN, Texas, Nov. 29, 2017 /PRNewswire/ — Genprex, Inc., a clinical stage gene therapy company, announced today that is has been selected as a finalist in this year’s Fierce Innovation Awards: Life Sciences Edition brought to you by the publisher of FierceBiotech and FiercePharma. Genprex was recognized as a finalist in the Fierce Technology Innovation Award category.

Genprex was selected as a finalist for its innovative lead product candidate, Oncoprex™ immunogene therapy, currently being studied in a Phase I/II clinical study for non-small cell lung cancer (NSCLC). Oncoprex is a unique, first-in-class multimodal therapy based on the Company’s proprietary platform technologies with the potential to sensitize cancer cells and enhance the therapeutic effect of other targeted therapies, such as checkpoint inhibitors and tyrosine kinase inhibitors. Combining the features of gene therapy, immunotherapy and nanotechnology, Oncoprex interrupts cell signaling pathways that promote replication and proliferation of cancer cells, re-establishes pathways for apoptosis (programmed cell death) in cancer cells, and modulates the body’s innate immune response against cancer cells. Preclinical and clinical data show that, if approved, Oncoprex may provide a novel treatment option for the majority of NSCLC patients who are not eligible for existing targeted therapies or may become resistant over time.

“We are very pleased to have been selected as a finalist for the Fierce Technology Innovation Award,” said Rodney Varner, CEO of Genprex. “Genprex is dedicated to advancing Oncoprex as a potential new treatment for non-small cell lung cancer and we are honored to be recognized alongside other companies working to improve the lives of patients in areas of high unmet medical need through unique scientific advances and innovation.”

Finalists’ applications were reviewed by an expert panel of judges to determine which companies demonstrate innovative technologies and services that have the potential to make the greatest impact for biotech and pharma companies. All applications were evaluated based on the following criteria: effectiveness, technical innovation, competitive advantage, financial impact, and true innovation. A full list of judges can be found at https://questex-lifesciences2017.secure platform.com/a/page/lifesciences-judges-2017.

Winners will be announced and featured in the Innovation Report scheduled to publish on Monday, December 11. To learn more about the Fierce Innovation Awards: Life Sciences Edition, please visit https://questex-lifesciences2017.secure-platform.com/a/.

To learn more about Genprex, visit https://www.genprex.com/.

About Genprex, Inc.

Genprex, Inc. is a clinical stage gene therapy company developing a new approach to treating cancer, based upon a novel proprietary technology

About The Author

Related posts

Leave a Reply

Your email address will not be published. Required fields are marked *